AYTU
Aytu BioPharma, Inc.
AYTU has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over AYTU overall, supported by stronger fundamentals and stronger modeled upside.
AYTU Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Stable | |
| Strong |
AYTU's balance sheet is currently strong, and its cash flow is stable, but its revenue and profitability are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
AYTU PE Valuation
AYTU has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
AYTU Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect AYTU's losses to shrink, with revenue growing.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
AYTU Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.66 | +$0.96 |
| Q1 2026 | -$4.08 | -$3.05 |
| Q4 2025 | -$3.34 | -$1.58 |
| Q3 2025 | -$2.55 | -$1.01 |
| Q2 2025 | -$2.62 | +$0.25 |
| Q1 2025 | -$1.03 | +$1.76 |
| Q4 2024 | -$1.76 | +$2.44 |
| Q3 2024 | -$1.54 | +$4.77 |
AYTU is still losing money, but far less than before: $1.66 per share over the past year, against $85.40 at its worst in early 2022.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over AYTU on earnings quality, reporting a profit while its opponent remains loss making.
AYTU Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $16.1M | +6.4% |
| Q1 2026 | $12.4M | -33% |
| Q4 2025 | $15.2M | -6.5% |
| Q3 2025 | $13.9M | -16% |
| Q2 2025 | $15.1M | -16% |
| Q1 2025 | $18.5M | +2.6% |
| Q4 2024 | $16.2M | -29% |
| Q3 2024 | $16.6M | -25% |
AYTU's revenue is recovering but still below its 2023 peak: $16M last quarter, up 6.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -4.8% | +46 points |
| Q1 2026 | -33% | -46 points |
| Q4 2025 | -13% | -2.5 points |
| Q3 2025 | -11% | -5.2 points |
| Q2 2025 | -50% | -30 points |
| Q1 2025 | 13% | +27 points |
| Q4 2024 | -10% | -21 points |
| Q3 2024 | -5.6% | +1.2 points |
AYTU's operating margin was −4.8% last quarter, up 46 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over AYTU on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over AYTU on profitability, with a higher operating margin.
AYTU Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $4.4M | +58% |
| Q1 2026 | -$4.2M | +$2.3M |
| Q2 2025 | $2.8M | +$3.6M |
| Q1 2025 | -$6.5M | -$6.3M |
| Q2 2024 | -$788K | -108% |
| Q1 2024 | -$254K | +$2.7M |
| Q4 2023 | -$135K | +$2.3M |
| Q3 2023 | -$211K | +$8.9M |
AYTU's free cash flow has turned positive after five years mostly in the red: $3M over the past year.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over AYTU on cash generation, producing positive trailing cash flow while its opponent burns cash.
AYTU Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +17% | +1.8M shares |
| 1 year | +50% | +4.1M shares |
| 3 years | +296% | +9.2M shares |
| 5 years | +6884% | +12.1M shares |
AYTU has 12M diluted shares, up 50% from a year ago.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over AYTU on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
AYTU Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2024 | -1.8x | Net Cash |
| Q1 2024 | -0.5x | Net Cash |
| Q4 2023 | -3.8x | Net Cash |
AYTU has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
AYTU Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.9 | Neutral |
| Stochastic | 8.0 | Oversold |
AYTU's weekly RSI is 36 (neutral) and its Stochastic is 8 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
AYTU PE vs Healthcare Sector
AYTU has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
AYTU Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.98 | 9.6% below |
| 20 week MA | $2.12 | 16% below |
| 50 week MA | $2.32 | 23% below |
| 100 week MA | $2.08 | 14% below |
| 200 week MA | $2.27 | 21% below |
AYTU is in a downtrend: it's below all five of its weekly moving averages, and 21% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over AYTU on trend strength, trading above more of its moving averages.
AYTU Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $196.0 | $122.4 | -38% |
| 2021 | $122.4 | $30.4 | -75% |
| 2022 | $30.4 | $3.80 | -88% |
| 2023 | $3.80 | $2.84 | -25% |
| 2024 | $2.84 | $1.52 | -46% |
| 2025 | $1.52 | $2.45 | +61% |
| 2026 YTD | $2.45 | $1.79 | -27% |
AYTU has finished lower in five of the last six years. It's down 27% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over AYTU on returns for 2026, with the stronger performance.